//
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial
Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study
A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study
Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction
Ticagrelor with or without Aspirin in High-Risk Patients after PCI